Drug intelligence / Profile preview

HealoTEAR

Development stage: Unknown
Lead developer: Healome Therapeutics
Administration: Ophthalmic, Topical

Overview

HealoTEAR is a preservative-free allogeneic serum eye drop formulation being developed by Healome Therapeutics for the treatment of moderate-to-severe dry eye disease, particularly cases with complex immune involvement and ocular surface damage. The product utilizes a proprietary formulation technology designed to enhance ocular surface lubrication, protection, and the retention of tears and therapeutic factors. Rather than targeting a specific molecular target, HealoTEAR acts as a biologic tear substitute, delivering serum-derived factors to create a pro-healing microenvironment on the ocular surface. It is currently in Phase 1 clinical development following MHRA approval.

Brand names: HealoTEAR
Other names: HealoTEAR (Dry Eye - complex)HealoTEAR (Glaucoma reformulation)HealoTEAR (Ocular surface disease reformulation)

Beyond the preview

Go deeper on HealoTEAR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HealoTEAR.

Explore the full profile